Personalised cancer medicine (Q26991908)

John D. Chester

series ordinal

2

1 reference

language of work or name

1 reference

15 July 2015

1 reference

International Journal of Cancer

published in

1 reference

volume

137

1 reference

issue

2

1 reference

page(s)

262-6

1 reference

Clinical pharmacogenomics of thiopurine S-methyltransferase

cites work

1 reference

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials

21 January 2018

1 reference

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

THE GENETICS OF BREAST CANCER SUSCEPTIBILITY

21 January 2018

1 reference

Meta-analysis of BRCA1 and BRCA2 penetrance

21 January 2018

1 reference

Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.

21 January 2018

1 reference

Detection of genetic alterations in hereditary colorectal cancer screening

21 January 2018

1 reference

Familial adenomatous polyposis

21 January 2018

1 reference

Restorative proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis revisited.

21 January 2018

1 reference

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

21 January 2018

1 reference

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

21 January 2018

1 reference

Chemoprevention of colorectal neoplasia: the potential for personalized medicine

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

The role of KIT in the management of patients with gastrointestinal stromal tumors

21 January 2018

1 reference

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

Synthetic lethality: general principles, utility and detection using genetic screens in human cells

21 January 2018

1 reference

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

Resistance to BRAF-targeted therapy in melanoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28940

1 reference

Consolidated OpenCitations Corpus – April 2017

2499135

2499135

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference